LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis (NCT02205762)

🧪 Interventions in This Study

• Prednisone (DRUG)
• Vinblastine (DRUG)
• mercaptopurine (DRUG)
• INDOMETHACIN (DRUG)
• Methotrexate (DRUG)
• Cytosine Arabinoside (DRUG)
• 2-chlorodeoxyadenosine (DRUG)
• Intravenous immunoglobulin (BIOLOGICAL)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Stratum I
2. Patients must be less than 18 years of age at the time of diagnosis.
3. Patients must have histological verification of the diagnosis of Langerhans cell histiocytosis according to the criteria described in Section 6.1
4. Signed informed consent form
5. Stratum II
6. Patients of Stratum I who have:
7. Progressive disease (AD worse) in non-risk organs after 6 weeks (Initial Course
8. AD intermediate or worse in non-risk organs or AD better in risk organs after 12 weeks (Initial Course 2)
9. Disease progression (AD worse) in non-risk organs at any time during continuation treatment
10. Active disease at the end of Stratum I treatment
11. Disease reactivation in non-risk organs at any time after completion of Stratum I treatment
12. Stratum III

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (42 Sites)

Showing the first 25 of 42 sites.

• Children's of Alabama — Birmingham, Alabama
• Phoenix Children's Hospital — Phoenix, Arizona
• Arkansas Children's Hospital — Little Rock, Arkansas
• Children's Hospital of Los Angeles — Los Angeles, California
• Valley Children's Healthcare — Madera, California
• UCSF Benioff Children's Hospital of Oakland — Oakland, California
• Children's Hospital of Orange County — Orange, California
• UCSF Helen Diller Family Cancer Center — San Francisco, California
• Connecticut Children's Medical Center — Hartford, Connecticut
• Children's National Medical Center — Washington D.C., District of Columbia
• Johns Hopkins All Children's Hospital — St. Petersburg, Florida
• Children's Healthcare of Atlanta, Emory — Atlanta, Georgia
• Ann & Robert H. Lurie Children's Hospital of Chicago — Chicago, Illinois
• Riley Hospital for Children - Indiana University — Indianapolis, Indiana
• Children's Mercy Hospitals — Kansas City, Kansas
• University of Kentucky A.B.Chandler Medical Center — Lexington, Kentucky
• University of Louisville, Norton Children's Hospital — Louisville, Kentucky
• Johns Hopkins University — Baltimore, Maryland
• Massachusetts General Hospital — Boston, Massachusetts
• Dana Farber Cancer Institute — Boston, Massachusetts
• Children's Minnesota — Minneapolis, Minnesota
• Hackensack University Medical Center — Hackensack, New Jersey
• Cohen Children's Medical Center — New Hyde Park, New York
• Mount Sinai Hospital — New York, New York
• Columbia University / Herbert Irving Cancer Center — New York, New York

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Langerhans Cell Histiocytosis

• Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib — Fort Worth, Texas
• Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH) — Palo Alto, California
• Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders — Phoenix, Arizona

Explore by condition: All Langerhans Cell Histiocytosis clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.